Skip to main content

Table 2 Significant differences of survival periods (months)

From: Prognostic factors in patients with metastatic spine tumors derived from lung cancer—a novel scoring system for predicting life expectancy

Factor

p value

Sex.

 Male:female

0.0803

 Age (years) ≤ 69 vs ≥ 70

0.8002

 Symptomatic level Cervical vs thoracic vs lumbosacral

0.1603

 Pathology Adenocarcinoma vs non-adenocarcinoma

0.0263*

Tokuhashi score

 General condition

 Poor vs good

0.0019*

 Moderate vs good

0.0321*

 Number of extraspinal bone metastases foci

0.9604

 Number of metastases in the vertebral body

0.1388

 Metastases to the major internal organs

0.6994

 Paralysis (spinal cord palsy)

0.0279*

 Total score ≤ 8 vs 9–10

0.1542

 ALP 400 IU/L ≥ or <

0.0961

 CEA 120 ng/ml ≥ or <

0.5189

 Molecular target drug, use (for ≥ 1 month) or not

0.0093*

 Bone-modifying agent, use or not

0.8650

  1. *Significant difference (p < 0.05). ALP indicates Alkaline phosphatase, CEA carcinoembryonic antigen